Important Information for TransMedics Securities Purchasers: Rosen Law Firm Reminds Investors of the Lead Plaintiff Deadline in Securities Class Action
New York, NY – Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023, and January 10, 2025 (the “Class Period”), of the significant April 15, 2025, lead plaintiff deadline in the securities class action first filed by the Firm. This notice is being issued to ensure potential claimants are aware of their rights and potential compensation.
What is a Securities Class Action?
A securities class action is a type of lawsuit filed on behalf of a large group of investors who have suffered similar losses due to alleged securities fraud. In this case, Rosen Law Firm is representing the class, and potential claimants can join the lawsuit without the need for any out-of-pocket costs or fees through a contingency fee arrangement.
Why is Rosen Law Firm Filing this Lawsuit?
The complaint alleges that TransMedics and certain of its executives and directors made false and misleading statements and failed to disclose material information during the Class Period, which artificially inflated the price of TransMedics securities. Specifically, the complaint alleges that TransMedics failed to disclose material information regarding the commercialization and regulatory approval of its Organ Care System (OCS), which is used to preserve donor lungs outside the body before transplantation. The complaint alleges that TransMedics’ statements were materially false and misleading at the time they were made.
What Should I Do if I Purchased TransMedics Securities During the Class Period?
If you purchased TransMedics securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline to apply for appointment is April 15, 2025. If you wish to serve as lead plaintiff, you must meet certain legal requirements and must be willing to help the class in the prosecution of the lawsuit. You may also choose to be an absent class member and do nothing if you wish to be bound by the court’s decisions in the case. The class will be represented by the law firms leading the litigation.
How Will this Affect Me?
If TransMedics is found to have committed securities fraud, investors who purchased the company’s securities during the Class Period may be able to recover their losses. The exact amount of compensation will depend on the size of their investment and the outcome of the case. If you are unsure about your eligibility or have questions about the process, you can contact Rosen Law Firm for a free consultation.
How Will this Affect the World?
The outcome of this case could have significant implications for the biotech industry and investor confidence in publicly traded companies. If the allegations are proven true, it could lead to increased scrutiny of companies in the industry and potentially result in more stringent regulations regarding disclosures and financial reporting. It could also serve as a reminder for investors to carefully research companies before investing and to be wary of potential red flags.
Conclusion
Rosen Law Firm is committed to ensuring that investors receive the compensation they are entitled to if they have been the victims of securities fraud. If you purchased TransMedics securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline to apply for appointment is April 15, 2025. For more information or to discuss your potential recovery, please contact Rosen Law Firm at 866-767-3653 or by email at [email protected].
The case is captioned In re TransMedics Group, Inc. Securities Litigation, case number 1:23-cv-05202, in the United States District Court for the Southern District of New York.
